Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.86 |
| ▸ | PGR | P06401 | 5/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.86 |
| ▸ | USP2 | O75604 | 5/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.84 |
| ▸ | MAPT | P10636 | 2/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.84 |
| ▸ | DRD2 | P14416 | 1/20 | 0.84 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | MLNR | O43193 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.73 |
| ▸ | PPARG | P37231 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14867458 | 0.99 | NR3C1 (0.84) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL10866660 | 0.98 | NR3C1 (0.83) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL10866655 | 0.98 | NR3C1 (0.83) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL10866663 | 0.98 | NR3C1 (0.83) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL11520052 | 0.97 | NR3C1 (0.90) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL3021328 | 0.96 | NR3C1 (0.81) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL9157442 | 0.96 | NR3C1 (0.85) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL3021332 | 0.95 | NR3C1 (0.83) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL29438083 | 0.95 | NR3C1 (0.83) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL9802343 | 0.95 | NR3C1 (0.86) | NR3C1PGRCYP3A4USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080038219-A1 | Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof | CALGENEX CORPORATION (US) | 2008-02-14 | — | — | US | claimed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | claimed |
| US-7175850-B2 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-02-13 | — | — | US | claimed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | claimed |
| JP-2002533379-A | — | — | 2002-10-08 | — | — | JP | claimed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | claimed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | claimed |
| WO-2023133460-A1 | IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS | CYRANO THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-7175850-B2 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | disclosed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
| US-5422361-A | A topical oil in water emulsions consisting of N-methylpyrrolidone/2-/ promoting drug delivery penetrating through skins | SCHERING CORPORATION (US) | 1995-06-06 | — | — | US | disclosed |
| WO-1991008733-A1 | STABLE CREAM AND LOTION BASES FOR LIPOPHILIC DRUG COMPOSITIONS | SCHERING CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | CUTA, LPO, GPX4 | NR3C1 4660/4885PGR 3545/4885CYP3A4 1398/4885 |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | GPX4, LPO, MMP8 | NR3C1 4351/4885PGR 2277/4885CYP3A4 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.